Chong Kun Dang opens a gene therapy research center and begins full-scale development of advanced biopharmaceuticals, a future growth engine.
Chong Kun Dang announced today that the opening ceremony of the gene therapy research center "Gen2C" was held at the Omnibus Park of Seoul St. Mary's Hospital on September 26, with about 50 officials, including Chong Kun Dang CEO Kim Young-joo and head of the Catholic University's Industry-Academic Cooperation Group Jo Seok-gu in attendance.
Gen2C is an abbreviation of “Gene to Cure”, meaning a gene for treatment. It reflects Chong Kun Dang's will to contribute to human health by developing innovative treatments using genes.
Chong Kun Dang plans to develop rare and intractable treatments for the Undruggable Target, which have high unmet demand and have been difficult to develop with existing methods, centering on the researchers in the gene therapy field of the Hyojong Research Institute.
In particular, it plans to focus on securing gene therapy products and its own platform technology using Adenovirus-Associated Virus (AAV), which has proven long-term efficacy and safety, as a carrier.
“The global cell and gene therapy market is expected to grow from $7.5 billion in 2021 to $55.6 billion in 2026, growing at a CAGR of about 49.1%," said an official from Chong Kun Dang. "Through the opening of the gene therapy research center, Chong Kun Dang plans to secure its own technology in the field and accelerate the development of global innovative new drugs.”
Meanwhile, Chong Kun Dang is expanding the scope of new drug development into advanced biopharmaceuticals such as gene therapy and cell therapy.
